PHAGE GP 2 TAB is a dual oral antidiabetic formulation combining Glimepiride 2 mg and Metformin Hydrochloride 500 mg (Sustained Release). It is designed for the effective management of Type 2 Diabetes Mellitus by combining insulinotropic and insulin-sensitizing mechanisms. Manufactured by Bluepill Express under internationally accredited facilities, it ensures consistent glycemic control, high safety standards, and global export readiness.

This product is manufactured under the Dr Precision label, ensuring GMP-compliant quality and precision formulation standards.

PHAGE GP 2 TAB is an advanced oral antidiabetic combination medication formulated to offer comprehensive glycemic control in patients diagnosed with Type 2 Diabetes Mellitus. It contains Glimepiride 2 mg and Metformin Hydrochloride 500 mg in a sustained-release matrix, synergistically working to reduce blood glucose levels through multiple metabolic pathways. This fixed-dose combination is especially suitable for patients who have not achieved sufficient glucose regulation through monotherapy and require escalation of treatment.

Glimepiride is a modern sulfonylurea that functions by enhancing the release of insulin from pancreatic β-cells. With a relatively longer half-life and high binding affinity to pancreatic receptors, Glimepiride provides stable and sustained insulinotropic action, reducing postprandial glucose spikes. The 2 mg dose in PHAGE GP 2 TAB is considered optimal for patients requiring moderate to advanced insulin stimulation, particularly those with suboptimal HbA1c values on lower-dose regimens.

Metformin, a biguanide-class agent, complements Glimepiride by improving insulin sensitivity and reducing hepatic glucose production. The 500 mg sustained-release component in this formulation ensures prolonged absorption and a steady plasma concentration of Metformin throughout the day. This delivery system significantly reduces the incidence of gastrointestinal disturbances typically associated with immediate-release Metformin while enhancing patient compliance.

Manufactured by Bluepill Express in internationally compliant facilities, PHAGE GP 2 TAB adheres to strict WHO-GMP, ISO, and HACCP standards. The product undergoes comprehensive in-process and post-production quality checks including dissolution studies, assay validation, impurity profiling, and real-time and accelerated stability testing. These processes ensure high therapeutic consistency, uniformity, and product integrity—making PHAGE GP 2 TAB suitable for both domestic and global distribution.

The formulation is ideal for adult patients with Type 2 Diabetes who require combination therapy to maintain target glycemic levels. It helps reduce both fasting plasma glucose and postprandial glucose values, while also contributing to HbA1c reduction over time. By combining the actions of two agents in a single tablet, PHAGE GP 2 TAB minimizes pill burden, improves compliance, and optimizes outcomes in diabetes care.

This tablet is typically administered once daily with the main meal, preferably breakfast or lunch, to coincide with peak insulin requirements and to mitigate the risk of hypoglycemia. The sustained-release matrix of Metformin facilitates prolonged glucose control, while Glimepiride’s rapid action covers immediate postprandial needs.

Bluepill Express offers full support for private labeling, custom packaging, and international documentation, including product dossiers, COAs, batch manufacturing records, and export-oriented technical files. The product can be customized for regional pharmacopeial standards including IP, BP, USP, or customized specifications based on client needs.

PHAGE GP 2 TAB is generally well tolerated. Common side effects may include mild gastrointestinal disturbances such as nausea or bloating in the initial days of therapy. Hypoglycemia is a potential concern with sulfonylureas but can be minimized with careful dose titration, adherence to prescribed meal timing, and proper patient education. The product is contraindicated in patients with Type 1 Diabetes, renal impairment, hepatic dysfunction, or known hypersensitivity to sulfonylureas or Metformin.